NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
4 trialsNCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting